ClinicalTrials.gg
CompletedNCT04959032Updated Oct 5, 2026Results posted

Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

A Phase 3 interventional study of Lumateperone 42 mg and Placebo in Schizophrenia, sponsored by Intra-Cellular Therapies, Inc.. Completed at 43 sites in 4 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Updated Oct 5, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
592
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing lumateperone in Schizophrenia — 3 open to participants now, 3 under way, 2 of them phase 3. lumateperone · Schizophrenia.

Enrollment
2nd of 12
592 · median 66
Started
2021
with 1 other
Phase 3
5 of 12
2 open now
Registered
8th of 12
by date
Lead sponsor
9 of 12
Intra-Cellular Therapies, Inc.

Among the 12 studies testing lumateperone in Schizophrenia, this one is the 2nd largest by enrollment, is one of 2 that started in 2021, is one of 5 in phase 3, and was the 8th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 12 studies testing lumateperone in Schizophrenia are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About lumateperone

lumateperone: first FDA approval 2019 (CAPLYTA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing lumateperone in Schizophrenia, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in adult patients with a primary diagnosis of schizophrenia according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5).

Read the detailed description

The study will be conducted in the following 5 phases:

  • A no-drug Screening Phase up to 7 days in duration during which patient eligibility will be assessed;
  • A 6-week, open-label Run-in Phase (RIP) during which all patients will receive oral lumateperone 42 mg/day;
  • A 12-week, open-label Stabilization Phase (SP) during which all patients will receive oral lumateperone 42 mg/day;
  • A Double-blind Treatment Phase (DBTP) 26 weeks in duration during which patients receive either lumateperone 42 mg or placebo (1:1 ratio);
  • A 2-week Safety Follow-up (SFU) Phase.
03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Relapse Prevention
  • Maintenance Design
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 to 60 years of age, inclusive.
  • Current diagnosis of schizophrenia according to criteria as determined by the modified Structured Clinical Interview for DSM-5 (modified SCID-5).
  • Diagnosis of schizophrenia for a minimum of 1 year before Visit 1.
  • Current psychotic episode \< 4 weeks duration at Visit 1.
  • PANSS total score ≥ 70 and ≤ 120 at Visit 1 and Visit 2.
  • Rating of at least 4 (moderate) on at least two of the following four PANSS positive symptoms: delusions (P1), hallucinatory behavior (P3), conceptual disorganization (P2), suspiciousness/persecution (P6) at Visit 1 and Visit 2.
  • Patient must identify a caregiver who provides consents to participate in the study.
  • In the opinion of the Investigator, the patient has significant risk for suicidal behavior during the course of his/her participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Currently meeting criteria for any of the following:

Schizoaffective disorder, schizophreniform disorder, and other psychotic disorders; Bipolar I or Bipolar II Disorder; Intellectual developmental disorder, delirium, dementia, amnestic and other cognitive disorders; Known or suspected borderline or antisocial personality disorder or other DSM 5 personality disorder of sufficient severity to interfere with participation in this study; Substance use disorder (other than nicotine) within the 3 months prior to Visit 1 of this study.

  • Patients in their first episode of psychosis.
  • Treatment-resistant schizophrenia over the last 2 years, defined as little or no symptomatic response to at least 2 courses of antipsychotic treatment of an adequate duration (at least 6 weeks) and at a therapeutic dose (according to the package insert for the antipsychotic treatment).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
592 participants (actual)

Study arms

  • Experimental
    Lumateperone 42 mg

    Drug: Lumateperone 42 mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Lumateperone 42 mg capsules administered orally, once daily.

  • DrugPlacebo

    Matching capsules administered orally, once daily.

06

What researchers measure

Primary outcomes

  1. Time to First Symptom Relapse During the Double-blind Treatment Phase

    Relapse during the DBTP was defined as meeting any one of the following criteria: * Psychiatric hospitalization or need for increased level of psychiatric care due to worsening of the patient's underlying condition; * Increase in PANSS total score by ≥ 30% for patients who scored 50 or higher at randomization or a 10-point or more increase in PANSS total score for patients who scored less than 50 at randomization ; * Increase in the Visit 14 CGI-S score by 2 or more points; * Deliberate self-injury or aggressive/violent behavior; * Any suicidal ideation or homicidal ideation; * Score of greater than 4 on 1 or more of the following PANSS items: P1, P2, P3, P6, P7, G8 or G14

    Time frame: Number of days from the randomization date to the first relapse date up to 26 weeks.

07

Results

Posted Oct 5, 2026

Participant flow

18 Week Open-label Treatment Phase
Participant flow — 18 Week Open-label Treatment Phase
MilestoneLumateperone 42 mg Open-label Treatment PhaseLumateperone 42 mg - Double-blind Treatment PhasePlacebo - Double-blind Treatment Phase
Started59200
Completed22800
Not completed36400
Withdrew: Adverse event5400
Withdrew: Lack of efficacy12200
Withdrew: Death100
Withdrew: Lost to follow-up4600
Withdrew: Protocol violation3500
Withdrew: Withdrawal by subject10400
Withdrew: Inability to identify a caregiver and patient incarceration200
26 Week Double-blind Treatment Phase
Participant flow — 26 Week Double-blind Treatment Phase
MilestoneLumateperone 42 mg Open-label Treatment PhaseLumateperone 42 mg - Double-blind Treatment PhasePlacebo - Double-blind Treatment Phase
Started0114114
Completed09498
Not completed02016
Withdrew: Adverse event022
Withdrew: Lost to follow-up043
Withdrew: Pregnancy001
Withdrew: Protocol violation052
Withdrew: Withdrawal by subject098

Outcome measures

PrimaryTime to First Symptom Relapse During the Double-blind Treatment Phase

Relapse during the DBTP was defined as meeting any one of the following criteria: * Psychiatric hospitalization or need for increased level of psychiatric care due to worsening of the patient's underlying condition; * Increase in PANSS total score by ≥ 30% for patients who scored 50 or higher at randomization or a 10-point or more increase in PANSS total score for patients who scored less than 50 at randomization ; * Increase in the Visit 14 CGI-S score by 2 or more points; * Deliberate self-injury or aggressive/violent behavior; * Any suicidal ideation or homicidal ideation; * Score of greater than 4 on 1 or more of the following PANSS items: P1, P2, P3, P6, P7, G8 or G14

Time frame:
Number of days from the randomization date to the first relapse date up to 26 weeks.
Reported as:
Median · days
Time to First Symptom Relapse During the Double-blind Treatment Phase
daysLumateperone 42 mgPlacebo
Time to First Symptom Relapse During the Double-blind Treatment PhaseNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Lumateperone 42 mg vs Placebo · Log Rank · p = 0.0002 · Hazard ratio (hr): 0.37 · 95% CI 0.22 to 0.65

Adverse events

Collected over From signing ICF until end of study procedures (up to 47 weeks), including 18 weeks of open-label treatment and up to 26 weeks of double-blind treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lumateperone 42 mg Open-label Treatment Phase1/592 (0.2%)23/592 (3.9%)85/592 (14.4%)
Lumateperone 42 mg Double-blind Treatment Phase0/110 (0%)1/110 (0.9%)9/110 (8.2%)
Placebo Double-blind Treatment Phase0/114 (0%)7/114 (6.1%)10/114 (8.8%)
Most frequent serious events
Most frequent serious events
EventLumateperone 42 mg Open-label Treatment PhaseLumateperone 42 mg Double-blind Treatment PhasePlacebo Double-blind Treatment Phase
SchizophreniaPsychiatric disorders9/5921/1106/114
Psychotic DisorderPsychiatric disorders7/5920/1100/114
Muscle InjuryInjury, poisoning and procedural complications0/5920/1101/114
Acute Kidney InjuryRenal and urinary disorders0/5920/1101/114
Suicidal IdeationPsychiatric disorders3/5920/1100/114
Intestinal ObstructionGastrointestinal disorders1/5920/1100/114
Covid-19Infections and infestations1/5920/1100/114
Acute PsychosisPsychiatric disorders1/5920/1100/114
Completed SuicidePsychiatric disorders1/5920/1100/114
Most frequent other events
Most frequent other events
EventLumateperone 42 mg Open-label Treatment PhaseLumateperone 42 mg Double-blind Treatment PhasePlacebo Double-blind Treatment Phase
HeadacheNervous system disorders78/5929/1104/114
SchizophreniaPsychiatric disorders9/5920/1106/114

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lumateperone 42 mg Open-label Treatment Phase
Mean42.5 ± 10.80
Sex: Female, Male
Sex: Female, Male(Participants)Lumateperone 42 mg Open-label Treatment Phase
Female178
Male414
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lumateperone 42 mg Open-label Treatment Phase
White299
Black or African American277
Asian8
Native Hawaiian or Other Pacific Islander1
Other2
Multiple5
Region of Enrollment
Region of Enrollment(participants)Lumateperone 42 mg Open-label Treatment Phase
United States382
Poland24
Bulgaria115
Serbia71
08

Study locations

43 sites
  • Clinical Site
    Little Rock, Arkansas 72211, United States
  • Clinical Site
    Bellflower, California 907006, United States
  • Clinical Site
    Cerritos, California 90703, United States
  • Clinical Site
    Culver City, California 90230, United States
  • Clinical Site
    Garden Grove, California 92845, United States
  • Clinical Site
    Lemon Grove, California 91945, United States
  • Clinical Site
    Montclair, California 91763, United States
  • Clinical Site
    Orange, California 92869, United States
  • Clinical Site
    Hollywood, Florida 33021, United States
  • Clinical Site
    Miami Lakes, Florida 33016, United States
  • Clinical Site
    Oakland Park, Florida 33334, United States
  • Clinical Site
    Atlanta, Georgia 30331, United States
  • Clinical Site
    Chicago, Illinois 60640, United States
  • Clinical Site
    Boston, Massachusetts 02114, United States
  • Clinical Site
    St Louis, Missouri 63141, United States
  • Clinical Site
    Las Vegas, Nevada 89102, United States
  • Clinical Site
    Berlin, New Jersey 08009, United States
  • Clinical Site
    North Canton, Ohio 44720, United States
  • Clinical Site
    Austin, Texas 78754, United States
  • Clinical Site
    DeSoto, Texas 75115, United States
  • Clinical Site
    Richardson, Texas 75080, United States
  • Clinical Site
    Burgas, 8000, Bulgaria
  • Clinical Site
    Kardzhali, 6600, Bulgaria
  • Clinical Site
    Kazanlak, 6100, Bulgaria
  • Clinical Site
    Lovech, 5500, Bulgaria
  • Clinical Site
    Novi Iskar, 1282, Bulgaria
  • Clinical Site
    Pleven, 5800, Bulgaria
  • Clinical Site
    Plovdiv, 4002, Bulgaria
  • Clinical Site
    Rousse, 7003, Bulgaria
  • Clinical Site
    Sofia, 1377, Bulgaria
  • Clinical Site
    Targovishte, 7700, Bulgaria
  • Clinical Site
    Tsarev Brod, 9747, Bulgaria
  • Clinical Site
    Tserova Koria, 5047, Bulgaria
  • Clinical Site
    Veliko Tarnovo, 5000, Bulgaria
  • Clinical Site
    Vratsa, 3000, Bulgaria
  • Clinical Site
    Gdansk, 80-214, Poland
  • Clinical Site
    Gdansk, 80-282, Poland
  • Clinical Site
    Gorlice, 3-8300, Poland
  • Clinical Site
    Tuszyn, 95080, Poland
  • Clinical site
    Belgrade, 11000, Serbia
  • Clinical Site
    Kovin, 26220, Serbia
  • Clinical Site
    Kragujevac, 34000, Serbia
  • Clinical Site
    Novi Kneževac, 23330, Serbia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Jul 2024, 36 months.

Results were first posted in Oct 2026, 2 years 2 months after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 36 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2021
First posted
Jul 12, 2021
StartActual
Jul 8, 2021
Primary completionActual
Jul 25, 2024
CompletionActual
Aug 7, 2024
Results first posted
Oct 5, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 5, 2026
Sites
4 sites added, 4 sites removed
Show 4 added (2 Poland, 1 United States, 1 Bulgaria)
  • Clinical Site · St Louis, United States
  • Clinical Site · Rousse, Bulgaria
  • Clinical Site · Gdansk, Poland
  • Clinical Site · Gdansk, Poland
Show 4 removed
  • Clinical Site · Saint Louis, United States
  • Clinical Site · Russe, Bulgaria
  • Clinical Site · Gdańsk, Poland
  • Clinical Site · Gdańsk, Poland
Oct 5, 2026
Enrollment
228→592
Oct 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedTime to first symptom relapse duringFirst Symptom Relapse During the Double-blind Treatment PhaseTime frame: Number of days from the randomization date to the first relapse date up to 26 weeks.
Oct 5, 2026
Documents
Show all 1 update
  1. Oct 5, 2026
    Results posted
    4 sites added, 4 sites removed
    Show 4 added (2 Poland, 1 United States, 1 Bulgaria)
    • Clinical Site · St Louis, United States
    • Clinical Site · Rousse, Bulgaria
    • Clinical Site · Gdansk, Poland
    • Clinical Site · Gdansk, Poland
    Show 4 removed
    • Clinical Site · Saint Louis, United States
    • Clinical Site · Russe, Bulgaria
    • Clinical Site · Gdańsk, Poland
    • Clinical Site · Gdańsk, Poland
    Enrollment 228→592
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedTime to first symptom relapse duringFirst Symptom Relapse During the Double-blind Treatment PhaseTime frame: Number of days from the randomization date to the first relapse date up to 26 weeks.
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04959032
Responsible party
Sponsor
First posted
Jul 12, 2021
Start date
Jul 8, 2021
Primary completion
Jul 25, 2024
Completion
Aug 7, 2024
Results posted
Oct 5, 2026
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lumateperone

Start the discussion